Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
We're at the moment engaged on utilizing medicine to govern sure enzymes to make most cancers cells extra vulnerable to ferroptosisThomas BrabletzLatest advances...
Two dose-limiting toxicities had been noticed, and the utmost tolerated dose was not reached in a research evaluating FS-1502 security, tolerability, and efficacy.FS-1502,...
